Perrigo Strategy and Business Model

Executive Overview

Perrigo is a consumer self-care company with an unusual mix: a large U.S. retailer-branded over-the-counter healthcare franchise and an international portfolio of owned OTC and wellness brands. Founded in 1887 in Allegan, Michigan, and now headquartered in Dublin, Perrigo sells products across pain relief, cough, cold and allergy, digestive health, smoking cessation, skincare, footcare, oral care, and women’s health. Its two reported segments are Consumer Self-Care Americas and Consumer Self-Care International. Perrigo reported about $4.4 billion of net sales in FY2023. Over the last several years, the company has reshaped itself away from prescription generics and toward a more focused consumer self-care portfolio, most notably through the sale of its generic Rx business and the acquisition of HRA Pharma. That shift matters strategically. The U.S. store-brand business provides scale, retailer relationships, and repeat-driven cash flow, while the international branded portfolio offers more brand equity and, in many categories, somewhat better pricing flexibility. The March 2024 rollout of Opill, the first over-the-counter daily birth control pill in the U.S., is the clearest recent signal that Perrigo is trying to add more differentiated growth engines to a historically value-oriented model.

Perrigo at a Glance

Logo
Common name	Perrigo
Full legal name	Perrigo Company plc
Headquarters	Dublin, Ireland
Ownership	Public company; widely held institutional ownership; no controlling shareholder publicly disclosed
Ticker	PRGO
Exchange	NYSE - New York Stock Exchange
Market Cap	$1.32B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1887 in Allegan, Michigan; acquired Elan in 2013 and moved tax domicile to Ireland; acquired Omega Pharma in 2014; sold generic Rx business in 2021; completed HRA Pharma acquisition in 2022; launched Opill in the U.S. in 2024
Industry or industries	Consumer self-care, over-the-counter healthcare, consumer health, private-label OTC manufacturing
Key products or services	Retailer-branded OTC medicines and wellness products; branded OTC and self-care products including women’s health, footcare, skincare, smoking cessation, and respiratory products
Geographic footprint	North America and Europe, with additional sales in Australia and selected international markets
Business segments as officially reported	Consumer Self-Care Americas; Consumer Self-Care International
Company website	https://www.perrigo.com/

1. What Is the Strategy of Perrigo?

1. 1a. What is the winning aspiration of Perrigo?

   Perrigo’s public purpose is to make lives better by bringing quality, affordable self-care products that consumers trust wherever they are sold. In practical strategy terms, its winning aspiration is to be a focused, pure-play consumer self-care company rather than a broader pharmaceutical company. That ambition became much clearer after the sale of the generic prescription business and the addition of HRA Pharma.

   Winning for Perrigo appears to mean three things at once: maintaining leadership in retailer-branded self-care in the U.S., building a stronger portfolio of owned international consumer health brands, and improving the quality of earnings through better mix, margins, and cash conversion. Perrigo’s FY2023 and early 2024 materials emphasize profitable growth, operational execution, and cash generation more than scale for its own sake. The company has not made one single long-range public number the centerpiece of the strategy; the direction is more important than a single metric.

2. 1b. Where does Perrigo play?

   Perrigo plays in consumer self-care categories where consumers can diagnose and treat common needs without a prescription or with light clinical intervention. Its core categories include pain relief, cough, cold and allergy, digestive health, smoking cessation, skincare, footcare, oral care, women’s health, and selected wellness products. It does not try to compete broadly across branded prescription pharmaceuticals.

   Geographically, Perrigo plays primarily in North America and Europe, with additional exposure to Australia and other international markets. Channel-wise, it serves mass retailers, drug chains, grocers, club stores, pharmacies, pharmacy wholesalers, and e-commerce platforms. Just as important, Perrigo has chosen two distinct economic arenas: retailer-owned brands in the Americas and company-owned brands in international markets. That choice shapes almost everything else about the business.

3. 1c. How does Perrigo plan to win?

   Perrigo’s plan to win is a dual model. In U.S. retailer-branded categories, it competes on value, quality, scale, reliable supply, and category management. National brands create the benchmark; Perrigo helps retailers offer a lower-priced alternative that can still meet regulatory and quality standards. That model depends on operational execution and retailer trust more than consumer advertising.

   In Consumer Self-Care International, Perrigo aims to win more through brand equity, category focus, and selective innovation. The HRA portfolio added brands and capabilities in women’s health and other consumer-health niches where product differentiation and consumer pull matter more. Opill is an example of how Perrigo is trying to add more differentiated growth: the company is not merely offering a cheaper substitute, but helping create and educate a new OTC category in the U.S.

4. 1d. What capabilities must Perrigo have in place?

   To make that strategy work, Perrigo needs a specific set of capabilities. First is regulated product development and quality assurance. OTC medicines, self-care products, and women’s health products still require disciplined regulatory, formulation, testing, and compliance capabilities. Second is manufacturing and supply-chain reliability. The U.S. retailer-branded business only works if large customers trust Perrigo to deliver on time, at consistent quality, and at a cost that preserves the retailer value proposition.

   Third is retailer-facing category management in the Americas and brand management in international markets. Those are different commercial muscles. Perrigo also needs strong integration and portfolio-management capabilities, because its current shape has been built through portfolio reshaping and acquisitions. Finally, data-driven demand planning matters more than it may appear at first glance because many OTC categories are seasonal, promotion-sensitive, and customer-specific.

5. 1e. What management systems does Perrigo require?

   Perrigo needs management systems that fit a regulated, multi-channel consumer health company. Quality systems and regulatory controls are foundational. Beyond that, service metrics such as fill rates, order-cycle reliability, inventory health, and forecast accuracy are strategically important, especially in Consumer Self-Care Americas where a missed shipment can jeopardize retailer relationships.

   The company also needs category-level profitability management, disciplined gross-margin tracking, and capital-allocation processes that distinguish between the cash-generating store-brand base and the investment needs of branded growth initiatives such as Opill. A practical reading of recent company communications suggests that Perrigo’s management systems increasingly focus on execution discipline: restoring service levels, improving productivity, measuring mix and margin, and making sure major launches and acquired brands receive enough operating attention to create returns rather than just revenue.

2. What Are the Current Strategic Initiatives of Perrigo?

Based on Perrigo’s FY2023 annual materials and early 2024 earnings commentary, the company’s near-term agenda is focused on execution, mix improvement, and selective innovation rather than a wholesale strategy reset.

• Scale the U.S. launch of Opill. Following U.S. Food and Drug Administration approval in July 2023, Perrigo began broad commercial rollout of Opill in 2024. This is strategically important because it gives Perrigo a differentiated women’s health asset, a brand-building opportunity, and a chance to participate in category creation rather than only competing inside mature store-brand categories.
• Stabilize execution in Consumer Self-Care Americas. Management commentary in late 2023 and early 2024 repeatedly emphasized improving service levels, demand planning, customer replenishment, and commercial execution in the Americas. For Perrigo, recovering lost sales and restoring retailer confidence can be as important as winning entirely new business.
• Shift mix toward higher-value branded self-care. The HRA acquisition broadened Perrigo’s international branded portfolio and strengthened its position in women’s health and selected adjacent categories. Perrigo’s current initiatives suggest continued focus on growing these brands across pharmacy, retail, and e-commerce channels.
• Improve gross margin and cash generation. Perrigo has emphasized productivity, procurement discipline, manufacturing efficiency, and price-cost management. In a business with retailer bargaining power and meaningful input-cost exposure, margin improvement is not a side issue; it is a core strategic initiative.
• Keep the portfolio focused on consumer self-care. Perrigo’s major portfolio actions over the last several years have moved the company away from prescription generics and toward a cleaner consumer self-care story. Recent public materials are consistent with continued discipline around focus, tuck-in capability building, and avoiding a return to less aligned businesses.
• Strengthen omnichannel execution. Perrigo’s categories increasingly require strong e-commerce availability, digital shelf execution, and online consumer education. This is especially relevant for owned brands such as Opill, where search, education, and conversion are part of market development.

3. What Is the Business Model of Perrigo?

What customers actually buy

Perrigo sells finished self-care products. In the Americas, customers often buy products that appear on the shelf under a retailer’s own brand rather than the Perrigo name. In international markets, customers buy Perrigo-owned brands such as Compeed, ellaOne, Opill, ACO, Mederma, and other regional OTC brands. Economically, the company sells health and wellness products that solve common, repeatable consumer needs at a price point below many branded alternatives or with targeted brand positioning in selected categories.

Recurring or repeat-driven versus one-time revenue

Perrigo’s model is highly repeat-driven, but not subscription-based. Most categories are replenishment categories: consumers repeatedly buy pain relief, allergy, digestive, skincare, footcare, smoking-cessation, or women’s health products as needs recur. Some categories are seasonal, especially cough, cold and allergy. Retailer shelf resets or launch shipments can create one-time spikes, but the underlying economics depend on repeat purchasing and regular replenishment.

How pricing power works

Pricing power is mixed. In retailer-branded OTC, Perrigo’s pricing power is constrained by large retail customers, competitive bidding, and the fact that store brands are positioned as value alternatives to national brands. In branded international self-care, Perrigo appears to have somewhat more pricing flexibility because brand equity, pharmacy recommendation, and category specialization matter more. Differentiated products such as Opill may also carry better pricing flexibility than a typical private-label analgesic or cold remedy.

Why the business mix matters

Business mix is central to understanding Perrigo. The Americas business offers scale, broad retailer access, and cash flow, but typically with tighter customer economics. The international branded portfolio may be smaller in absolute scale, but it can offer better margins, stronger brand economics, and more resilient differentiation. Perrigo’s portfolio reshaping over the last several years reflects an effort to lean more into that second engine without giving up the first.

What drives gross margin, operating margin, and cash generation

Gross margin depends heavily on product mix, manufacturing efficiency, input costs, freight, packaging costs, and service reliability. If Perrigo misses shipments or runs inefficiently, margins can erode quickly. Operating margin also depends on selling, general, and administrative expense, especially marketing support for international brands and new-product launches. Cash generation is driven by inventory discipline, working capital management, capital spending levels, and the stability of large retailer relationships. This is a finished-goods consumer healthcare model, not a software or recurring-service model; execution in manufacturing and distribution shows up directly in cash flow.

4. What Products and/or Services Does Perrigo Sell?

Consumer Self-Care Americas

In Consumer Self-Care Americas, Perrigo primarily sells retailer-branded OTC and self-care products. These commonly include categories such as pain and sleep aids, cough, cold and allergy remedies, digestive health products, smoking-cessation products, oral care, skincare, first aid, diagnostics, and selected vitamins, minerals and supplements. A defining feature of this business is that consumers often buy the product under a retailer’s private label, even though Perrigo is the manufacturer.

Consumer Self-Care International

In Consumer Self-Care International, Perrigo sells owned brands, largely through pharmacies, retailers, and e-commerce channels. Publicly visible brands include Compeed in footcare, ellaOne and Opill in women’s health, ACO and Mederma in skincare and scar care, and certain regional OTC brands such as Solpadeine, Bronchostop, and NiQuitin in selected markets.

Which offerings matter most

The U.S. retailer-branded portfolio appears to remain the larger revenue base and an important source of operating leverage. Strategically, however, the international branded portfolio and newer women’s health assets matter disproportionately because they can strengthen Perrigo’s brand mix, margin profile, and growth narrative. Opill is the clearest newer growth offering. By contrast, mature store-brand categories are more likely to be cash-generative core businesses than the main source of strategic excitement.

5. What Are the Key Competitors or Peers of Perrigo?

Perrigo faces two overlapping competitive sets: large branded consumer-health companies that compete for the same consumer need and shelf space, and private-label manufacturers that compete for retailer programs. The table below mixes direct competitors and the closest public peers.

6. What Is the Marketing Strategy of Perrigo?

Perrigo’s marketing strategy is best understood as a two-track model. In Consumer Self-Care Americas, marketing is less about mass consumer brand advertising and more about retailer-facing category management. Perrigo helps customers design a compelling value alternative to national brands through product assortment, packaging architecture, price gaps, shelf positioning, and category insights. In that business, marketing is a supporting commercial capability tied closely to sales and customer management.

In Consumer Self-Care International, marketing is more consumer-facing. Perrigo’s owned brands require traditional brand-building tools such as pharmacy activation, digital marketing, consumer education, packaging and messaging, and in some cases media support. This is especially true in women’s health and self-care categories where awareness, trust, and education affect adoption.

Opill shows the difference clearly. Launching the first OTC daily birth control pill in the U.S. requires more than shelf placement; it requires education, search visibility, clear usage communication, and trust-building. For Perrigo overall, marketing is not the single defining capability of the company, but it becomes much more strategically important as the mix shifts toward owned brands and differentiated consumer categories.

7. What Are the Key Customer Segments of Perrigo?

• Large U.S. retailers. Mass merchants, drug chains, grocers, club stores, and other large retailers are critical customers for Perrigo’s retailer-branded business. This customer group likely accounts for a meaningful share of company revenue and gives the Americas business a more concentrated customer structure than the international branded business.
• Pharmacies and pharmacy wholesalers. In Europe and other international markets, pharmacies and pharmacy-led distribution matter more because many self-care brands are purchased through pharmacy channels or are influenced by pharmacist recommendation.
• E-commerce platforms and omnichannel retailers. Online availability increasingly matters across both segments. In some categories, especially newer brands or education-led purchases, digital channels are strategically important rather than incremental.
• End consumers. Even where Perrigo sells through retailers, the true economic demand driver is the consumer managing a recurring self-care need. In the U.S. store-brand model, Perrigo often reaches that consumer indirectly through retailer brands. In the international business, it reaches the consumer more directly through owned brands.

Perrigo is reasonably diversified by category and geography, but customer concentration is still an important feature in the U.S. retailer-branded business because a limited number of large retail chains have significant purchasing power.

8. What Is the Sales Model of Perrigo?

Perrigo primarily sells through business-to-business channels rather than through its own retail network. In Consumer Self-Care Americas, sales are typically handled directly with large retail customers through account teams that manage category reviews, pricing, assortment, promotions, new product introductions, and replenishment. This is a relationship-intensive model with a strong key-account component.

In Consumer Self-Care International, Perrigo uses a mix of direct sales to retailers and pharmacies, country-level commercial organizations, and distributors or pharmacy wholesalers depending on the market. The channel mix is more fragmented than in the U.S. and tends to require stronger local brand and commercial execution.

Channel structure has important strategic consequences. In the U.S., large retailer concentration can pressure pricing and service expectations, but it also creates scale once Perrigo is designed into a retailer’s private-label assortment. In international branded markets, Perrigo has more opportunity to shape demand through brand pull, but it must manage country-by-country commercialization complexity. That mix creates good use cases for consultants in key-account strategy, channel economics, and omnichannel growth.

9. In What Geographies Does Perrigo Operate?

Perrigo operates primarily in North America and Europe, with additional sales in Australia and selected other international markets. Its geographic profile is broad enough to matter strategically, but it is not evenly distributed; the U.S. remains its largest market.

• United States. The U.S. is Perrigo’s most important commercial market, especially for retailer-branded OTC and wellness products. Perrigo’s historic operating roots are in Michigan, and its commercial and operational footprint in the U.S. remains central to the business.
• Europe. Europe is the core geography for Perrigo’s international branded self-care business. Through Omega Pharma and HRA Pharma, the company has meaningful brand and commercial presence across markets such as France, the United Kingdom, Belgium, Ireland, the Netherlands, the Nordics, and other parts of Western Europe.
• Other international markets. Perrigo also serves markets outside North America and Europe, including Australia and selected export markets, typically through local channel partners, distributors, or country organizations.

Corporate headquarters are in Dublin, Ireland. In practice, Perrigo operates with major leadership, commercial, and operational hubs across both the U.S. and Europe. That split reflects the company’s history as a U.S.-rooted manufacturer that later became Ireland-domiciled and more internationally branded through acquisitions.

10. Who Are the Owners of Perrigo?

Perrigo is a publicly traded company with no controlling shareholder publicly disclosed. As of early 2024, ownership was broadly institutional, with large asset managers such as The Vanguard Group, BlackRock, and State Street appearing among the significant shareholders in public filings. That ownership profile means Perrigo is effectively governed as a widely held public company rather than a founder-controlled, family-controlled, or private-equity-controlled business.

11. How Is Perrigo Organized?

Perrigo is legally organized as an Irish public limited company, but operationally it runs as a consumer self-care company with two main reporting segments: Consumer Self-Care Americas and Consumer Self-Care International. That segment structure is important because each business has a different commercial logic. The Americas business is more retailer and private-label oriented; the international business is more brand and country oriented.

At a practical level, Perrigo appears to combine segment-level commercial accountability with centralized support functions such as quality, regulatory affairs, finance, procurement, supply chain, and parts of product development. The company is not simply a passive holding company for brands. It is an operating business that must coordinate manufacturing, regulatory control, customer service, and commercial execution across geographies and channels.

12. How Does Perrigo Operate?

Perrigo operates as a regulated finished-goods manufacturer and marketer. Day to day, the company creates value through a sequence of tightly linked activities:

1. Sourcing. Perrigo procures active ingredients, excipients, packaging materials, and other inputs required for OTC and self-care products.
2. Formulation and manufacturing. Products are made in Perrigo facilities and, where appropriate, with external manufacturing partners. This includes category-specific know-how in tablets, creams, patches, footcare, oral care, and other formats.
3. Quality and regulatory release. Because the products sit in regulated health categories, Perrigo must manage testing, quality systems, labeling compliance, and country-specific regulatory requirements.
4. Pack-out and channel customization. In the U.S. store-brand business, packaging and assortment often need to be tailored to the retailer. In the branded international business, packaging and claims may vary by country and channel.
5. Distribution and replenishment. Perrigo ships into retail and pharmacy channels, manages inventory and seasonal demand, and works to maintain service levels that preserve shelf position and customer trust.
6. Innovation and portfolio management. The company continually refreshes products, manages launches, and decides which categories deserve more brand investment or operational support.

The biggest operational complexities are service reliability, seasonality, retailer concentration, country-by-country regulation, and the need to run both a private-label and a brand-led commercial model at the same time.

13. What Are the Growth Opportunities for Perrigo?

Based on management commentary and a reasonable external reading of the business, Perrigo’s most plausible growth opportunities are the following:

• Build Opill into a meaningful U.S. women’s health platform. Opill is not just a product launch; it is a category-creation opportunity. If Perrigo can build awareness, retail availability, and repeat use, it could create a differentiated revenue stream with better brand economics than much of the traditional store-brand portfolio.
• Recover and grow Consumer Self-Care Americas through better execution. In a retailer-driven model, better service levels can translate directly into regained shelf share, improved customer relationships, and volume recovery. This may be one of the most immediate sources of growth if execution improves.
• Expand international brands. The HRA and Omega portfolios give Perrigo growth levers in women’s health, skincare, footcare, respiratory, and selected OTC categories across Europe. Geographic expansion, channel expansion, and better brand support can all add growth.
• Improve mix toward higher-margin categories. Even without very high revenue growth, Perrigo can create value by shifting sales toward brands, differentiated formats, and categories with better pricing dynamics.
• Use e-commerce more effectively. Digital search, online conversion, and consumer education are increasingly important in self-care. Products that require education or discreet purchase behavior may particularly benefit.
• Selective acquisitions and partnerships. Perrigo’s recent history suggests that tuck-in M&A can be an important growth tool, especially where it adds brands, capabilities, or category positions aligned with consumer self-care.

The main constraints are large-retailer bargaining power in the U.S., execution risk in supply chain and launches, regulatory complexity, and the challenge of turning a historically private-label-heavy company into a stronger owner of consumer-facing brands.

14. What Is the History of Perrigo?

• 1887: Perrigo was founded in Allegan, Michigan, initially as a packager and seller of home remedies and medicines.
• 20th century: The company developed into a major manufacturer of store-brand healthcare products, building a durable role as a behind-the-scenes supplier to retailers.
• 2013: Perrigo acquired Elan, a move that shifted the group’s tax domicile to Ireland and reshaped the corporate structure.
• 2014: Perrigo acquired Omega Pharma, significantly expanding its European OTC and consumer-health footprint.
• 2015: Perrigo drew wide market attention when it rejected a hostile takeover attempt by Mylan.
• 2019: Perrigo acquired Ranir Global Holdings, adding scale in oral care and strengthening parts of its retailer-branded offering.
• 2021: Perrigo sold its generic Rx pharmaceuticals business, a major milestone in its transformation toward a pure-play consumer self-care company.
• 2022: Perrigo completed the acquisition of HRA Pharma, adding important consumer-health brands and strengthening women’s health and European brand capabilities.
• 2023 to 2024: The FDA approved Opill for over-the-counter use in the U.S. in 2023, and Perrigo launched it commercially in 2024.

15. What Are the Key Suppliers to Perrigo?

Perrigo does not publicly provide a broad named supplier roster in the way some industrial companies do, but supplier structure is strategically important because the company operates in regulated health categories with large retailer commitments.

• Active ingredients and specialty health inputs. Perrigo depends on suppliers of pharmaceutical ingredients and category-specific materials used in OTC products, smoking-cessation products, women’s health, skincare, and footcare.
• Excipients and formulation materials. Fillers, binders, creams, gels, coatings, and other formulation inputs matter to cost, manufacturability, and regulatory consistency.
• Packaging suppliers. Bottles, blisters, cartons, labels, and tamper-evident packaging are important both for compliance and for retailer-specific pack formats.
• Contract manufacturers and service partners. In categories where Perrigo uses external manufacturing or specialist capabilities, those relationships can affect resilience and speed to market.
• Logistics providers. Transportation and warehousing partners matter because service failures can directly affect retailer shelf availability.

Supplier management matters strategically because Perrigo needs quality assurance, regulatory compliance, continuity of supply, and enough sourcing flexibility to avoid disruption in high-volume customer programs.

16. What Are the Key Brands Owned by Perrigo?

Brand ownership is strategically more important in Consumer Self-Care International than in Perrigo’s U.S. retailer-branded business. Several brands stand out:

In the Americas, many Perrigo-made products are sold under retailer names rather than Perrigo-owned consumer brands. That is why brand strategy is a bigger strategic lever in the international segment.

17. How Does the Supply Chain of Perrigo Function?

Perrigo’s supply chain is central to its competitiveness because the company sells regulated, replenishment-driven products into channels that punish stockouts. The supply chain has to be low cost, reliable, and flexible enough to handle customer-specific packaging and seasonal swings.

1. Sourcing. Perrigo secures active ingredients, excipients, specialty materials, and packaging from a mix of suppliers.
2. Manufacturing and pack-out. Products are manufactured internally and, where appropriate, by third parties, then packed into retailer-branded or Perrigo-owned branded formats.
3. Quality release. Regulated testing and batch release are essential before products can move into commerce.
4. Warehousing and distribution. Finished goods move into retailer, pharmacy, and wholesaler channels. In the U.S. store-brand business, service reliability is especially critical because customers are large and concentrated.
5. Demand planning and seasonal management. Categories such as cough, cold and allergy can create demand spikes, so forecasting and inventory positioning matter.

Strategically, the supply chain matters because a company like Perrigo can lose revenue quickly if fill rates fall, launches slip, or working capital swells. In other words, supply-chain execution is not just an operations issue; it is part of the commercial value proposition.

18. What Is the Finance Strategy of Perrigo?

Perrigo’s finance strategy in recent years has been shaped by portfolio transformation. After major divestitures and acquisitions, the company’s financial priorities have centered on improving earnings quality, supporting targeted growth investments, maintaining balance-sheet discipline, and converting more profit into cash.

In practical terms, that means a few things. First, Perrigo appears focused on reinvesting behind core consumer self-care categories and launches such as Opill rather than spreading capital across unrelated businesses. Second, deleveraging and disciplined balance-sheet management have been important following the HRA acquisition. Third, working capital control matters because the business carries meaningful inventory, serves large retailers, and must support seasonal demand swings.

Perrigo also maintains a dividend, which signals that shareholder returns remain part of the finance story. At least in recent public materials, however, the more strategic financial emphasis has appeared to be on margin recovery, cash generation, and portfolio focus rather than on aggressive share repurchases or highly leveraged capital allocation.

19. What Major Acquisitions Has Perrigo Made?

Acquisitions have played a major role in Perrigo’s strategic evolution, especially in moving the company from a U.S.-centered private-label business toward a broader consumer self-care platform.

The pattern is clear: Perrigo has used M&A and portfolio actions not simply to get bigger, but to reshape the company toward branded, consumer-facing self-care categories and away from prescription generics.

20. How Companies Like Perrigo Leverage Independent Consultants through Umbrex

Companies like Perrigo often need high-caliber problem solvers for focused strategic or execution-heavy workstreams without hiring a full large-firm consulting team. Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including many alumni of McKinsey, Bain, BCG, and other top firms. For a company with Perrigo’s mix of retailer-branded manufacturing, international brand building, regulated products, supply-chain complexity, and current growth initiatives, the most relevant projects are usually practical, cross-functional, and time-bounded.

• Consumer self-care portfolio strategy. Assess where Perrigo should concentrate investment across U.S. store-brand categories, international brands, and women’s health.
• Opill growth strategy and launch analytics. Build consumer segmentation, pricing scenarios, channel priorities, and repeat-purchase tracking for the U.S. OTC birth-control market.
• Service-level recovery in Consumer Self-Care Americas. Diagnose forecasting, inventory, and distribution bottlenecks and design an execution-improvement program for key retailers.
• Retail key-account strategy. Improve joint business planning, category management, and negotiation strategy for large U.S. mass, drug, grocery, and club customers.
• Gross-margin improvement. Run SKU rationalization, product-mix optimization, manufacturing productivity, and procurement savings initiatives.
• International brand expansion. Develop market-entry and channel-expansion plans for brands such as Compeed, ellaOne, ACO, or other regional self-care assets.
• Pricing and trade architecture. Redesign price ladders, retailer trade terms, promotional effectiveness, and country-level price positioning across categories.
• M&A screening and integration support. Evaluate tuck-in consumer self-care acquisitions, build synergy cases, and support post-merger integration.
• Working-capital and cash-conversion improvement. Improve inventory policies, supply-chain planning, and cash discipline across a seasonal, multi-country product portfolio.
• Digital commerce and AI-enabled demand planning. Upgrade e-commerce execution, digital shelf analytics, and forecasting tools for seasonal OTC categories and new-product launches.